All In Biotech

Drug Trial Radar · NCT01052025

Curcumin Therapy in Patients With Impaired Glucose Tolerance and Insulin Resistance

Antiatherogenic and Antimetabolic Effect of Curcumin Therapy in the Prevention and Delay of Type 2 Diabetic in Patients With Impaired Glucose Tolerance and Insulin Resistance

Last checked: Nov 20, 2026Latest source record: Jan 20, 2010 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingRandomized with 200 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

200

Planned (sponsor's estimate)

Start

Aug 2009

Primary completion

Mar 2010

Study completion Apr 2010

Sponsor

Lead sponsor
Srinakharinwirot UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Ministry of Health, Thailand
First posted
Jan 20, 2010

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Single (investigator)
Primary purpose
Prevention
Who can join
All sexes, from 35 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The incidence rate of type 2 diabetes in Thai populations is high and increasing every year. Cardiovascular disease is the main complication of this disease, which has been defined as an important cause of death among Diabetic patients. This disease is now becoming a major health problem and causes a great economic loss to the country. Evidence shows that Curcumin, Thai herbal medicine, has the effectiveness of prevention and delay of type 2 diabetes. However, there is no scientific study that aims to prove the efficacy of this herb particularly for prevention and delay the disease in Patients with impaired glucose tolerance (pre-diabetes) and insulin resistance.

Conditions

  • Type 2 Diabetes
  • Pre-diabetes
  • Insulin Resistance
  • Cardiovascular Risk

Interventions

  • CurcuminDrug

    curcumin capsule contains 250 mg curcuminoiods, 3 capsules per time, 2 times a day before meal for 12 months

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. To examine the efficacy of curcumin on the delay of degenerative beta-cells in pancrease for protection of Type 2 Diabetes in patients with impaired glucose tolerance (Pre-diabetes)Time frame: 12 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • HRH Princess Maha Chakri Sirindhorn Medical Center

    Ongkarak, Nakornnayok, Thailand · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.